NEW YORK, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for ...
During the Quarter, Amaero continued to execute on its strategy to establish a scaled, cost-competitive U.S. domestic ...
Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025 Published Apr 29, 2025 8:53pm EDT ...
NEW YORK, July 30, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent ...
NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback